Sepsis occurs when chemicals released in the bloodstream as a result of an infection trigger production of endotoxins causing inflammation throughout the body. This causes a systemic inflammatory cascade of changes that damage multiple organ systems, leading them to fail, and often results in death.
Researchers at Rogosin have developed a lipid emulsion as a new therapy that augments the natural ability of circulating lipoproteins to neutralize and clear toxins from gram-negative bacteria from the bloodstream. These toxins are responsible for causing sepsis. Benefits of the emulsion over other approaches include: (1) broad effectiveness against microbial toxins unlike antibody therapies which are very specific, (2) the emulsion amplifies a natural defense against microbial toxins, unlike receptor blockers or antibody therapies that disable normal functions, and (3) a three-day continuous intravenous infusion of the emulsion provides sustained protection across the critical early hours of septic shock. A Phase II/III clinical trial is currently being designed and is expected to begin in 6 months.